Different Oral Antithrombotic Therapy for the Treatment of Ventricular Thrombus: An Observational Study from 2010 to 2019

Table 2

Outcomes of thrombus resolution in patients with an imaging follow-up at different time points (N (%)).

Thrombus resolution	NOACs (n = 53)	VKAs (n = 92)	Antiplatelet therapy (n = 67)	value
6 weeks	27 (50.94)	20 (21.74)	16 (23.88)	0.0005
12 weeks	37 (69.81)	38 (41.3)	31 (46.27)	0.0032
6 months	44 (83.02)	63 (68.48)	44 (65.67)	0.0844
12 months	46 (86.79)	71 (77.17)	55 (82.09)	0.3515

Note: a total of 251 patients were lost to the imaging follow-up: 246 (98%) patients had the phone review without the image reports, and five other patients were dead not until the first visit follow-up at 6 weeks, three (1.2%) patients in the VKAs group died from heart failure during the initial hospitalization, and two (0.8%) patients in the APT group due to the aggravating multiorgan diseases, separately occurring at 25 days later after discharge. Calculated by Chi-square test. VT: ventricular thrombus; N: number of patients; NOACs: non-vitamin K antagonist oral anticoagulants; VKAs: vitamin K antagonists; APT: antiplatelet therapy.